LGND Ligand Pharmaceuticals (LGND) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000886163
Congress · 1Form 144 · 4
Insider buyers, 180 days
0
Funds added, last quarter
250
13F, latest reported quarter
Conversions, 180 days
18
Codes C/M, not in net · $3.8M priced
What the filings say about LGND
Insiders, 180 days
-$25.1M net sold
8 sellers · 18% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-05-29
Planned sales (Form 144), 90 days
$15.9M
4 notices
Ligand Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, LIGAND PHARMACEUTICALS INC insiders sold a net $25.1M of stock across 199 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 61 earlier Form 4 trades (code P or S) here by this insider (61 sales), the last on Sep 3, 2026.
- The trade is 2.3% of the 36,021 shares held after it.
- 1 other insider sold within 30 days.
- 250 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CLO & Secretary Reardon Andrew sold about $252.0K of LGND under a 10b5-1 plan on Oct 2, 2026; 1 other insider sold within 30 days and 250 funds added in the latest 13F quarter.Context
- 61 earlier Form 4 trades (code P or S) here by this insider (61 sales), the last on Sep 3, 2026.
- The trade is 5.8% of the 34,045 shares held after it.
- 1 other insider sold within 30 days.
- 250 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CLO & Secretary Reardon Andrew sold about $599.8K of LGND under a 10b5-1 plan on Oct 2, 2026; 1 other insider sold within 30 days and 250 funds added in the latest 13F quarter.Context
- 61 earlier Form 4 trades (code P or S) here by this insider (61 sales), the last on Sep 3, 2026.
- The trade is 4.7% of the 32,510 shares held after it.
- 1 other insider sold within 30 days.
- 250 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CLO & Secretary Reardon Andrew sold about $467.4K of LGND under a 10b5-1 plan on Oct 2, 2026; 1 other insider sold within 30 days and 250 funds added in the latest 13F quarter.Context
- 61 earlier Form 4 trades (code P or S) here by this insider (61 sales), the last on Sep 3, 2026.
- The trade is 1.3% of the 32,106 shares held after it.
- 1 other insider sold within 30 days.
- 250 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CLO & Secretary Reardon Andrew sold about $123.7K of LGND under a 10b5-1 plan on Oct 2, 2026; 1 other insider sold within 30 days and 250 funds added in the latest 13F quarter.Context
- 61 earlier Form 4 trades (code P or S) here by this insider (61 sales), the last on Sep 3, 2026.
- The trade is 0.7% of the 31,871 shares held after it.
- 1 other insider sold within 30 days.
- 250 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CLO & Secretary Reardon Andrew sold about $72.2K of LGND under a 10b5-1 plan on Oct 2, 2026; 1 other insider sold within 30 days and 250 funds added in the latest 13F quarter.199 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$25.1M over 180 days
-$16.1M over 90 days
below 89% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
250 funds bought in last quarter
more than 93% of Pharma & Biotech
Revenue
+60.4% year over year
more than 79% of Pharma & Biotech
Margin
46.4% net margin
more than 94% of Pharma & Biotech
Buybacks
$60.0M repurchased, FY to 2026-06-30
more than 59% of Pharma & Biotech
Short interest
12.8% of the float short (float per yahoo 2026-10-27) · 10.5 days to cover · settled 2026-10-15
more than 80% of Pharma & Biotech
What changed in the last 30 days
Oct 6CLO & Secretary Reardon Andrew sold $1.5M under a 10b5-1 plan (Oct 2)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Watch LGND
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+66.4%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns LGND: institutional holders (13F)
13F holdings, latest reported quarter
3,100,996 sh
$980.2M
1,201,644 sh
$379.8M
1,138,316 sh
$359.8M
1,040,578 sh
$328.9M
870,950 sh
$275.3M
Congress trades in LGND
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-05-29 · disclosed 10 days later
$1,001 - $15,000
Bought 2026-03-03 · disclosed 35 days later
$1,001 - $15,000
Bought 2026-01-15 · disclosed 29 days later
$1,001 - $15,000
Bought 2026-01-05 · disclosed 39 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
LGND planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
MARTINE ZIMMERMANN
Filed 2026-09-10
$342.0K
ANDREW REARDON
Filed 2026-09-03
$4.3M
OCTAVIO ESPINOZA
Filed 2026-08-12
$9.1M
Jason Haas
Filed 2026-08-12
$2.1M
ANDREW REARDON
Filed 2026-07-01
$3.2M
LGND mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ranger Micro Cap Fund
$652.7K position · as of 2026-07-31
5.6%
DWS Small Cap Core Fund
$63.2M position · as of 2026-06-30
5.4%
Impax Small Cap Fund
$48.2M position · as of 2026-06-30
5.1%
Franklin Genomic Advancements ETF
$1.3M position · as of 2026-06-30
4.6%
Ranger Small Cap Fund
$555.2K position · as of 2026-07-31
4.5%
Transamerica Small Cap Growth
$3.6M position · as of 2026-07-31
4.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Todd C.Davis
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$12.9M
$21.7M
$6.6M
+58%
-7%
2023
$6.2M
$5.1M
$2.8M
+5%
-6%
2021
$9.6M
$16.0M
$5.0M
+55%
+0%
2020
$5.8M
$6.8M
$2.8M
-5%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $25.1M sold by insiders over 180 days, 250 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $15.9M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
LGND financials
Revenue growth
+60.4%
XBRL, annual
Net margin
46.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$290.5M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM LGND
| FY Dec 2025 | $268.1M |
| FY Dec 2024 | $167.1M |
| FY Dec 2023 | $131.3M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $63.7M |
| Mar 2026 | $51.7M |
| Dec 2025 | $59.7M |
| Sep 2025 | $115.5M |
| Jun 2025 | $47.6M |
| Mar 2025 | $45.3M |
| Dec 2024 | $42.8M |
| Sep 2024 | $51.8M |
At each fiscal year end
Single quarter
Net margin, TTM
+67.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM LGND
| FY Dec 2025 | +46.4% |
| FY Dec 2024 | -2.4% |
| FY Dec 2023 | +39.7% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +76.2% |
| Mar 2026 | -25.8% |
| Dec 2025 | +75.1% |
| Sep 2025 | +101.6% |
| Jun 2025 | +10.2% |
| Mar 2025 | -93.6% |
| Dec 2024 | -72.6% |
| Sep 2024 | -13.8% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$131.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM LGND
| FY Dec 2025 | $48.9M |
| FY Dec 2024 | $95.2M |
| FY Dec 2023 | $46.1M |
| FY Dec 2022 | $119.9M |
| FY Dec 2021 | $70.0M |
| Jun 2026 | $24.0M |
| Mar 2026 | $48.5M |
| Dec 2025 | $45.9M |
| Sep 2025 | $13.1M |
| Jun 2025 | $15.6M |
| Mar 2025 | -$25.7M |
| Dec 2024 | $27.8M |
| Sep 2024 | $35.9M |
At each fiscal year end
Single quarter
Debt to equity
1.16x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity LGND
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.39x |
| Jun 2026 | 1.16x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.12x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt LGND
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.25x |
| Jun 2026 | 0.12x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+22.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity LGND
| FY Dec 2025 | +13.5% |
| FY Dec 2024 | -0.5% |
| FY Dec 2023 | +8.0% |
| FY Dec 2022 | -4.7% |
| FY Dec 2021 | +7.5% |
| Jun 2026 | +22.0% |
| Mar 2026 | +17.1% |
| Dec 2025 | +13.5% |
| Sep 2025 | +5.4% |
| Jun 2025 | -9.5% |
| Mar 2025 | -16.6% |
| Dec 2024 | -0.5% |
| Sep 2024 | +6.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+12.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets LGND
| FY Dec 2025 | +9.9% |
| FY Dec 2024 | -0.5% |
| FY Dec 2023 | +6.7% |
| FY Dec 2022 | -3.2% |
| FY Dec 2021 | +4.3% |
| Jun 2026 | +12.6% |
| Mar 2026 | +12.6% |
| Dec 2025 | +9.9% |
| Sep 2025 | +4.0% |
| Jun 2025 | -8.4% |
| Mar 2025 | -14.6% |
| Dec 2024 | -0.5% |
| Sep 2024 | +5.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+5.3%
operating income after a 17.1% effective tax rate, over long-term debt only, 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital LGND
| FY Dec 2025 | +4.0% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +1.6% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +5.3% |
| Mar 2026 | +9.6% |
| Dec 2025 | +4.0% |
| Sep 2025 | +1.7% |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -1.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+6.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed LGND
| FY Dec 2025 | +3.4% |
| FY Dec 2024 | -2.7% |
| FY Dec 2023 | +1.7% |
| FY Dec 2022 | +0.3% |
| FY Dec 2021 | +8.2% |
| Jun 2026 | +6.3% |
| Mar 2026 | +8.1% |
| Dec 2025 | +3.4% |
| Sep 2025 | +1.5% |
| Jun 2025 | -4.0% |
| Mar 2025 | -7.1% |
| Dec 2024 | -2.7% |
| Sep 2024 | -1.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
32.76x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing LGND
| FY Dec 2025 | 32.10x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 24.63x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 29.11x |
| Jun 2026 | 33.59x |
| Mar 2026 | 26.87x |
| Dec 2025 | 32.10x |
| Sep 2025 | 87.26x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 39.88x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$6.3B
market value at close 2026-10-26 on 2026-08-04 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value LGND
| FY Dec 2025 | $3.5B |
| FY Dec 2024 | $2.0B |
| FY Dec 2023 | $1.2B |
| FY Dec 2022 | $1.1B |
| FY Dec 2021 | $1.9B |
| Jun 2026 | $6.5B |
| Mar 2026 | $3.9B |
| Dec 2025 | $3.5B |
| Sep 2025 | $3.3B |
| Jun 2025 | $2.1B |
| Mar 2025 | $2.0B |
| Dec 2024 | $2.0B |
| Sep 2024 | $1.8B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+2.1%
TTM free cash flow over market value at close 2026-10-26
FCF yield LGND
| FY Dec 2025 | +1.3% |
| FY Dec 2024 | +4.7% |
| FY Dec 2023 | +3.7% |
| FY Dec 2022 | +10.6% |
| FY Dec 2021 | +4.3% |
| Jun 2026 | +2.1% |
| Mar 2026 | +3.1% |
| Dec 2025 | +1.3% |
| Sep 2025 | +0.9% |
| Jun 2025 | +2.4% |
| Mar 2025 | +2.5% |
| Dec 2024 | +4.7% |
| Sep 2024 | +4.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing LGND
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 0.19x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $268.1M | $167.1M | $131.3M | $196.2M |
| Operating income | $41.0M | -$22.6M | $11.9M | $3.0M |
| Net income | $124.5M | -$4.0M | $52.2M | -$33.4M |
| EPS (diluted) | 6.13 | -0.22 | 2.94 | -1.98 |
| Operating cash flow | $49.4M | $97.0M | $49.6M | $137.8M |
| Cash | $174.9M | $72.3M | $23.0M | $45.0M |
| Long-term debt | n/a | n/a | n/a | $0 |
| Buybacks | $15.0M | $0 | $0 | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
LGND Stock Sonar score 6/7 axes
Find similar shapesCompareLGND ranks highest on growth (79th percentile) and institutional and government (77th), and lowest on insider conviction (5th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
LGND filings, in plain words
Are Ligand Pharmaceuticals insiders buying or selling LGND?
In the 180 days to 2026-10-28, Ligand Pharmaceuticals insiders were net sellers, a net $25.1M across purchases and sales reported on Form 4, by 8 sellers.
Have members of Congress traded LGND?
Yes. In the year to 2026-10-28, 1 House member disclosed buying LGND and 0 House members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-05-29.
Are there planned insider sales of LGND?
Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $15.9M of stock; the latest, by MARTINE ZIMMERMANN, was filed 2026-09-10.
Read the full summary
In the 180 days to 2026-10-28, Ligand Pharmaceuticals insiders were net sellers of LGND, a net $25.1M across purchases and sales reported on Form 4 by 8 sellers. 18% of the 62 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-28, 1 member of Congress disclosed buying LGND and 0 members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-05-29. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $15.9M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
